Mohr D C, Hart S L, Fonareva I, Tasch E S
University of California, Veterans Administration Medical Center, San Francisco 94121, USA.
Mult Scler. 2006 Apr;12(2):204-8. doi: 10.1191/135248506ms1265oa.
The objective of this study was to examine the adequacy of antidepressant pharmacotherapy in a sample of patients with multiple sclerosis (MS) treated by neurologists.
MS patients under the care of neurologists were recruited from a large health maintenance organization. Major depressive disorder (MDD) was diagnosed using a structured telephone interview. Antidepressant treatment data were obtained from the HMO pharmacy database.
Study participants included 260 patients with MS treated by 35 neurologists. A total of 67 (25.8%) patients met the criteria for MDD. Among the patients with MDD, 65.6% received no antidepressant medication, 4.7% received subthreshold doses from their neurologists, 26.6% received doses at threshold, and 3.1% received doses exceeding threshold.
Depression was undertreated by the neurologists treating this sample of patients with comorbid MS and MDD. Potential solutions are discussed.
本研究的目的是在一组由神经科医生治疗的多发性硬化症(MS)患者样本中,检验抗抑郁药物治疗的充分性。
从一个大型健康维护组织招募接受神经科医生治疗的MS患者。使用结构化电话访谈诊断重度抑郁症(MDD)。抗抑郁治疗数据从健康维护组织药房数据库中获取。
研究参与者包括由35名神经科医生治疗的260例MS患者。共有67例(25.8%)患者符合MDD标准。在患有MDD的患者中,65.6%未接受抗抑郁药物治疗,4.7%从神经科医生处接受低于阈值剂量的药物,26.6%接受阈值剂量的药物,3.1%接受超过阈值剂量的药物。
治疗该合并MS和MDD患者样本的神经科医生对抑郁症治疗不足。文中讨论了可能的解决办法。